Jeffrey Cohen

May 21, 2024 | law.com | Jeffrey Cohen

For decades, student-athletes have asserted that colleges and universities have benefitted from their participation in collegiate athletics, while the student athletes themselves receive nothing in return. A college scholarship certainly has value; however, student-athletes have pushed for more, using the court system for the past 15 years to advance their cause, and the entire sports landscape is still trying to figure out what is legal and what balance to strike.

Oct 31, 2023 | neurologylive.com | Jeffrey Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

WATCH TIME: 12 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s. Yet, with all of the change that advances in pharmaceutical development have brought, there are still novel approaches being introduced—and perhaps the biggest recent introduction is biosimilars.

Oct 29, 2023 | neurologylive.com | Jeffrey Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

WATCH TIME: 9 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s. Yet, with all of the change that advances in pharmaceutical development have brought, there are still novel approaches being introduced—and perhaps the biggest recent introduction is biosimilars.

Oct 27, 2023 | neurologylive.com | Jeffrey Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

October 27, 2023Jeff Cohen, MD, and Alicyn Magruder, PharmD, BCACP, MSCS, discuss the best practices when switching to a biosimilar therapy, including patient education and when to consider an insurance appeal. [WATCH TIME: 7 minutes]WATCH TIME: 7 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s.